SEC Form 4 Filing for Roger Sawhney

On September 18, 2026, Roger Sawhney, a director at Arbutus Biopharma Corp, engaged in several transactions involving the company's common shares. Sawhney exercised stock options, acquiring 52,533 shares at $3.34 per share and an additional 78,800 shares at $4.24 per share. In a related transaction, 100,508 shares were withheld to cover exercise prices, with a price of $5.07 per share. Following these transactions, Sawhney holds 30,825 common shares directly. Additionally, options to acquire 52,533 shares at $3.34 and 78,800 shares at $4.24 were exercised and disposed of, resulting in 105,067 shares held indirectly through options and 0 shares held indirectly after the second option exercise. The reporting person is Roger Sawhney, and the filing is a Form 4.